May 21, 2021
PharmaCCX is pleased to announce that Mel Walker has joined the company's advisory board where he will advise on the company's strategy based on his years of leadership within the pharma industry.
"We are excited to have Mel join the PharmaCCX team in our pursuit of improved negotiations that result in patients getting treatments in a more timely fashion. Mel's abundant experience within the pharma industry will be a valuable input to our product development and how we engage with our customers" said Nathan Sigworth, CEO of PharmaCCX.
With over 20 years of experience in the Pharmaceutical Industry, Mel is passionate about ensuring that patients can access innovative therapies while creating value and growth for companies with whom he works. Mel has a track record for delivering strategies that enhance price and payer positioning, and for shaping clinical programs to optimize patient outcomes and increase overall return on R&D investments.
"I’m excited to join the PharmaCCX advisory board for a number of reasons" said Mel Walker. "Firstly, I believe that the technology being developed has the potential to dramatically improve the negotiation process between Payers and Pharma - this will become a must-have tool as outcomes-based agreements increasingly become a pre-requisite for new medicines. Secondly, I am impressed by the team's passion and unwavering commitment to being an independent and unbiased neutral party. Thirdly and most importantly, by working together on this mission, we can improve the chances of patients getting faster access to life changing new therapies."
Prior to joining PharmaCCX, Mel has held leadership roles with Roche, GSK and Otsuka, leading teams responsible for market access, pricing, health economics, public affairs, business development, pipeline strategy, digital health, and product launch. He also been an active member of various senior decision making boards in global R&D, BD, digital health and corporate strategy.
Currently, through BioPharma Futures, a company he founded in 2020, Mel advises small companies on commercial strategy with a particular focus on value creation during clinical development. Mel’s vision and understanding of healthcare helps companies to navigate key trends, improve asset valuations, and, most importantly, optimize patient access.
He holds additional roles a a Strategic Advisor to Eleusis Therapeutics and as a member of NDA Group’s Advisory Board which brings together ex-regulators and senior industry leaders known for their expertise in regulatory affairs, pharmacovigilance and HTA.
Mel has co-authored over 30 research papers and abstracts, 2 book chapters, and has worked in a wide range of therapeutic areas. He regularly chairs international conferences on Pricing, Reimbursement, Innovative Payment Mechanisms, HTA Regulatory Interactions, Evidence Generation, and Digital Health. He has a degree in Pharmacy and a PhD in Health Outcomes, both from the University of Wales, Cardiff.
I believe that the technology being developed has the potential to dramatically improve the negotiation process between Payers and Pharma...